Bristol Myers Squibb has reported positive top-line results from the registrational Phase II QUINTESSENTIAL trial of arlocabtagene autoleucel in adults with quadruple-class exposed relapsed and refractory multiple myeloma. The study is evaluating the efficacy and safety of arlocabtagene autoleucel in patients who have previously received CAR T-cell therapies.
Arlocabtagene autoleucel is an autologous G protein-coupled receptor class C group 5 member D-directed chimeric antigen receptor T cell therapy. The multi-centre, single-arm, open-label study achieved its primary endpoint, with a statistically significant and clinically meaningful overall response rate in patients who had received at least four prior lines of therapy.
These prior treatments included immunomodulatory, proteasome inhibitors, anti-cluster of differentiation 38 therapies, and B-cell maturation antigen-targeted therapies. The trial is described as the first to assess a treatment in this patient population following exposure to prior B-cell maturation antigen-targeted therapies.
Key secondary endpoints were also met, with the therapy achieving a complete response rate in relapsed and refractory multiple myeloma patients who had been quadruple-class exposed after four or more previous treatments. Additionally, arlocabtagene autoleucel showed key secondary endpoint results for overall response rate and complete response rate in patients who had received at least three prior lines of therapy.
Treatment Options Expanding
The safety profile observed was in line with that of other CAR T-cell and GPRC5D-targeting therapies in multiple myeloma. Bristol Myers Squibb cell therapy organisation president Lynelle Hoch said: “As combination treatment regimens are now frequently used in earlier lines of therapy, an increasing number of people with multiple myeloma are quadruple-class exposed and resistant to currently available therapies earlier in the treatment journey, creating a critical need for new therapeutic approaches.
“These top-line results support arlocabtagene autoleucel’s potential benefit for patients while showing a safety profile consistent with expectations. They highlight the value of targeting alternative proteins, like GPRC5D, with the power of cell therapy to transform outcomes, laying the foundation for arlocabtagene autoleucel to become an important treatment option for this emerging group of patients who have been exposed to prior B-cell maturation antigen-targeted therapies.”
Given the positive results from the QUINTESSENTIAL trial, arlocabtagene autoleucel could become a key treatment option for patients with relapsed and refractory multiple myeloma who have been exposed to prior B-cell maturation antigen-targeted therapies. The study’s findings may also inform future research into the use of CAR T-cell therapies in this patient population.
Innovation Beyond Myeloma
Earlier this year, Bristol Myers Squibb reported positive top-line results from the Phase III SCOUT-HCM trial assessing Camzyos for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. The company’s continued innovation in multiple myeloma and other areas may lead to new treatment options for patients with complex medical needs. They are working to develop new therapies.
Lynelle Hoch’s statement emphasizes the need for new treatments. The QUINTESSENTIAL trial is a step towards addressing this need.
Bristol Myers Squibb is committed to developing innovative therapies. The company’s work in multiple myeloma is an example of this commitment.
The QUINTESSENTIAL trial’s focus on patients who have received prior CAR T-cell therapies is particularly significant, as it highlights the potential for arlocabtagene autoleucel to provide a new treatment option for those who have exhausted other available therapies. By targeting the GPRC5D protein, arlocabtagene autoleucel offers a distinct approach to treating multiple myeloma, which could lead to improved outcomes for patients with this debilitating disease.
The study’s results also show the importance of continued research into the use of CAR T-cell therapies in multiple myeloma. As the treatment environment for this disease continues to evolve, it is likely that new and innovative therapies will be developed, providing hope for patients who have limited treatment options. With its commitment to innovation and patient care, Bristol Myers Squibb is well-positioned to play a leading role in this effort.
